Development of Anti-M13 Antibodies
Updated time: 2020-07-24 10:58:54
Development of Anti-M13 Antibodies
Docket Number
10T-1090714
Announcement Date
2020-07-24
IP Status
Know-how
Abstract
We have developed two Anti-M13 antibodies which are more specific and binding affinity than the anti-M13 antibody sold by GE in the past and have been discontinued. According to the analysis of ELISA and flow cytometry to compare the currently available antibody products, these two Anti-M13 antibodies still have better binding ability. Therefore, these two antibodies have commercial advantages.
Technological Advantages
- The binding abilities of ELISA and flow cytometry are better than the current commercially available antibodies and the products sold by GE in the past.
- There are two high-quality Anti-M13 antibody products.
Applications of Technology
- They can be sold for bio-industry, research, and legal entities with phage platforms at home and abroad.
Inventor
Han-Chung Wu
Contact person
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office
Download Files

Development of Anti-M13 Antibodies